NeonMind Biosciences Inc (TSE:LCR)
:LCR
Want to see TSE:LCR full AI Analyst Report?
LCR Stock Chart & Stats
C$0.04
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.04
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.02 - C$0.08
Previous CloseN/A
Volume126.00K
Average Volume (3M)290.69K
Market Cap
C$2.77M
Enterprise ValueC$2.75M
Total Cash (Recent Filing)C$206.03K
Total Debt (Recent Filing)C$1.14M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding92,499,870
10 Day Avg. Volume583,757
30 Day Avg. Volume290,695
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)-9.40
Price to Sales (P/S)0.00
P/FCF Ratio-6.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Psilocybin-based Mental Health R&DA dedicated focus on psilocybin-based therapies targets a clearly defined, large unmet mental-health segment. This specialization supports development of deep scientific expertise and program continuity, improving odds of creating proprietary assets that can drive long-term licensing or therapeutic adoption if clinical progress is achieved.
R&D-to-licensing Business ModelA model centered on R&D leading to patents and licensing allows NeonMind to commercialize via partners rather than scale large in-house commercialization. This can preserve capital, leverage partners' distribution, and create recurring royalty-style revenues as clinical programs mature, fostering a durable path to monetization if IP is generated.
Improving Cash-flow Trend Versus Prior YearReported improvement in free-cash-flow versus 2024 suggests operational progress or better cash management. While still negative, a stabilizing cash-flow trend reduces immediate funding pressure and lengthens runway, making staged clinical development and milestone attainment more feasible over the coming months.
Bears Say
No Recurring Revenue And Persistent LossesA multi-year absence of meaningful revenue means the company's value and sustainability depend heavily on R&D outcomes and external funding. Persistent net losses erode financial flexibility, increase dependency on capital markets or partners, and heighten execution and dilution risk until commercial revenues emerge.
Negative Shareholders' EquityNegative shareholders' equity signals accumulated losses that weaken solvency and constrain access to traditional financing. Over time this can limit strategic options, raise borrowing costs, and force dilutive equity raises or expensive partnership terms to fund clinical programs and operations.
Consistent Negative Operating And Free Cash FlowSustained negative operating and free cash flow necessitates repeated external financing to fund trials and operations. Reliance on external capital increases execution risk, potential for dilution, and managerial focus on fundraising rather than program advancement, creating a material constraint on long-term value creation.
NeonMind Biosciences Inc News
LCR FAQ
What was NeonMind Biosciences Inc’s price range in the past 12 months?
NeonMind Biosciences Inc lowest stock price was C$0.01 and its highest was C$0.08 in the past 12 months.
What is NeonMind Biosciences Inc’s market cap?
NeonMind Biosciences Inc’s market cap is C$2.77M.
When is NeonMind Biosciences Inc’s upcoming earnings report date?
NeonMind Biosciences Inc’s upcoming earnings report date is Aug 05, 2026 which is in 96 days.
How were NeonMind Biosciences Inc’s earnings last quarter?
NeonMind Biosciences Inc released its earnings results on Mar 03, 2026. The company reported -C$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.003.
Is NeonMind Biosciences Inc overvalued?
According to Wall Street analysts NeonMind Biosciences Inc’s price is currently Overvalued.
Does NeonMind Biosciences Inc pay dividends?
NeonMind Biosciences Inc does not currently pay dividends.
What is NeonMind Biosciences Inc’s EPS estimate?
NeonMind Biosciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NeonMind Biosciences Inc have?
NeonMind Biosciences Inc has 92,499,870 shares outstanding.
What happened to NeonMind Biosciences Inc’s price movement after its last earnings report?
NeonMind Biosciences Inc reported an EPS of -C$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of NeonMind Biosciences Inc?
Currently, no hedge funds are holding shares in TSE:LCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NeonMind Biosciences Inc
Lancaster Resources Inc. engages in the acquisition, exploration, and development of mineral properties and renewable energy projects. It has option to acquire a 100% interest in the Alkali Flat lithium brine project situated in Lordsburg, New Mexico, the United States. The company is based in West Vancouver, Canada.
Technical Analysis
Options Prices
Currently, No data available
---